top of page
Publications
רשימת פרסומים
1: Dobosz P, Stempor PA, Roszik J, Herman A, Layani A, Berger R, Avni D, Sidi Y,
Leibowitz-Amit R. Checkpoint Genes at the Cancer Side of the Immunological
Synapse in Bladder Cancer. Transl Oncol. 2019 Dec 20;13(2):193-200. doi:
10.1016/j.tranon.2019.10.018. [Epub ahead of print] PubMed PMID: 31869744.
2: Percik R, Shlomai G, Tirosh A, Tirosh A, Leibowitz-Amit R, Eshet Y, Greenberg
G, Merlinsky A, Barhod E, Steinberg-Silman Y, Sella T. Isolated autoimmune
adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause
of adrenal insufficiency related to check point inhibitors. Autoimmun Rev. 2019
Dec 12:102454. doi: 10.1016/j.autrev.2019.102454. [Epub ahead of print] Review.
PubMed PMID: 31838158.
3: Petrylak DP, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after
platinum-based therapy (RANGE): overall survival and updated results of a
randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Nov 18. pii:
S1470-2045(19)30668-0. doi: 10.1016/S1470-2045(19)30668-0. [Epub ahead of print]
PubMed PMID: 31753727.
4: Bar J, Markel G, Gottfried T, Percik R, Leibowitz-Amit R, Berger R, Golan T,
Daher S, Taliansky A, Dudnik E, Shulman K, Urban D, Onn A. Acute vascular events
as a possibly related adverse event of immunotherapy: a single-institute
retrospective study. Eur J Cancer. 2019 Oct;120:122-131. doi:
10.1016/j.ejca.2019.06.021. Epub 2019 Sep 10. PubMed PMID: 31518968.
5: Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN,
Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni
D, Markel G, Leibowitz-Amit R. TNFSF4 (OX40L) expression and survival in locally
advanced and metastatic melanoma. Cancer Immunol Immunother. 2019
Sep;68(9):1493-1500. doi: 10.1007/s00262-019-02382-0. Epub 2019 Sep 9. PubMed
PMID: 31501955.
6: Motzer RJ, et al; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1370-1385.
doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol.
2019 Aug 21;:. PubMed PMID: 31427204.
7: O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ,
Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ.
A phase 2 trial of sunitinib in patients with progressive paraganglioma or
pheochromocytoma: the SNIPP trial. Br J Cancer. 2019 Jun;120(12):1113-1119. doi:
10.1038/s41416-019-0474-x. Epub 2019 May 20. PubMed PMID: 31105270; PubMed
Central PMCID: PMC6738062.
8: Leibowitz-Amit R. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James,
et al's Letter to the Editor re: The Case Against the European Medicines Agency's
Change to the Label for Radium-223 for the Treatment of Metastatic
Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53. Eur Urol. 2019
Jul;76(1):e19. doi: 10.1016/j.eururo.2019.03.013. Epub 2019 Mar 28. PubMed PMID:
30928161.
9: Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R,
Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering
Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi:
10.1200/CCI.17.00054. PubMed PMID: 30652536; PubMed Central PMCID: PMC6873994.
10: Hammer L, Laufer M, Dotan Z, Leibowitz-Amit R, Berger R, Felder S, Weiss I,
Lawrence YR, Symon Z. Accelerated Hypofractionated Radiation Therapy for Elderly
Frail Bladder Cancer Patients Unfit for Surgery or Chemotherapy. Am J Clin Oncol.
2019 Feb;42(2):179-183. doi: 10.1097/COC.0000000000000491. PubMed PMID: 30451730.
11: Kaiser J, Li H, North SA, Leibowitz-Amit R, Seah JA, Morshed N, Chau C,
Lee-Ying R, Heng DYC, Sridhar S, Crabb SJ, Alimohamed NS. The Prognostic Role of
the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in
Patients with Muscle-Invasive Bladder Cancer: A Retrospective,
Multi-Institutional Study. Bladder Cancer. 2018 Apr 26;4(2):185-194. doi:
10.3233/BLC-170133. PubMed PMID: 29732389; PubMed Central PMCID: PMC5929304.
12: Motzer RJ, et al; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi:
10.1056/NEJMoa1712126. Epub 2018 Mar 21. PubMed PMID: 29562145; PubMed Central
PMCID: PMC5972549.
13: Abu-Ghanem Y, Ramon J, Berger R, Kaver I, Fridman E, Leibowitz-Amit R, Dotan
ZA. Positive surgical margin following radical nephrectomy is an independent
predictor of local recurrence and disease-specific survival. World J Surg Oncol.
2017 Nov 2;15(1):193. doi: 10.1186/s12957-017-1257-6. PubMed PMID: 29096642;
PubMed Central PMCID: PMC5668980.
14: Mizrahi A, Barzilai A, Gur-Wahnon D, Ben-Dov IZ, Glassberg S, Meningher T,
Elharar E, Masalha M, Jacob-Hirsch J, Tabibian-Keissar H, Barshack I, Roszik J,
Leibowitz-Amit R, Sidi Y, Avni D. Alterations of microRNAs throughout the
malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in
epithelial to mesenchymal transition of keratinocytes. Oncogene. 2018 Jan
11;37(2):218-230. doi: 10.1038/onc.2017.315. Epub 2017 Sep 18. PubMed PMID:
28925390.
15: Petrylak DP, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after
platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6.
Epub 2017 Sep 12. PubMed PMID: 28916371.
16: Saad A, Goldstein J, Lawrence YR, Spieler B, Leibowitz-Amit R, Berger R,
Davidson T, Urban D, Tsang L, Alezra D, Weiss I, Symon Z. Classifying high-risk
versus very high-risk prostate cancer: is it relevant to outcomes of conformal
radiotherapy and androgen deprivation? Radiat Oncol. 2017 Jan 6;12(1):5. doi:
10.1186/s13014-016-0743-2. PubMed PMID: 28061904; PubMed Central PMCID:
PMC5216523.
17: Leibowitz-Amit R, Israel A, Gal M, Atenafu EA, Symon Z, Portnoy O, Laufer M,
Dotan Z, Ramon J, Avni D, Fridman E, Berger R. Association between the Absolute
Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy
in Muscle-invasive Bladder Cancer. Clin Oncol (R Coll Radiol). 2016
Dec;28(12):790-796. doi: 10.1016/j.clon.2016.07.007. Epub 2016 Aug 5. PubMed
PMID: 27498850.
18: Bonen H, Kol N, Shomron N, Leibowitz-Amit R, Quagliata L, Lorber T, Sidi Y,
Avni D. Promoter-Associated RNAs Regulate HSPC152 Gene Expression in Malignant
Melanoma. Noncoding RNA. 2016 Jun 30;2(3). pii: E7. doi: 10.3390/ncrna2030007.
PubMed PMID: 29657265; PubMed Central PMCID: PMC5831909.
19: Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT,
Chi KN, Joshua AM. Changes in plasma biomarkers following treatment with
cabozantinib in metastatic castration-resistant prostate cancer: a post hoc
analysis of an extension cohort of a phase II trial. J Transl Med. 2016 Jan
13;14:12. doi: 10.1186/s12967-015-0747-y. PubMed PMID: 26762579; PubMed Central
PMCID: PMC4712499.
20: Zehavi L, Schayek H, Jacob-Hirsch J, Sidi Y, Leibowitz-Amit R*, Avni D.
MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in
malignant melanoma. Mol Cancer. 2015 Mar 26;14:68. doi:
10.1186/s12943-015-0338-9. PubMed PMID: 25889255; PubMed Central PMCID:
PMC4392476.* Equal corresponding author
21: Seah JA, Leibowitz-Amit R*, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM,
Sridhar SS. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant
Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin
Cancer. 2015 Aug;13(4):e229-e233. doi: 10.1016/j.clgc.2015.02.001. Epub 2015 Feb
7. PubMed PMID: 25777682. * equal contribution
22: Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, Eisenberger
MA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, Weitzen
R, Berger R. Is there a "Trial Effect" on Outcome of Patients with Metastatic
Renal Cell Carcinoma Treated with Sunitinib? Cancer Res Treat. 2016
Jan;48(1):281-7. doi: 10.4143/crt.2014.289. Epub 2015 Mar 5. PubMed PMID:
25761478; PubMed Central PMCID: PMC4720089.
23: Leibowitz-Amit R, Khoja L, Tannock IF, Joshua AM. Choosing a better end point
for trials of bone-protective agents. Ann Oncol. 2015 May;26(5):1032-3. doi:
10.1093/annonc/mdv039. Epub 2015 Jan 28. PubMed PMID: 25632065.
24: Leibowitz-Amit R, Templeton AJ, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF,
Joshua AM. Efficacy and toxicity of abiraterone and docetaxel in octogenarians
with metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2015
Jan;6(1):23-8. doi: 10.1016/j.jgo.2014.09.183. Epub 2014 Oct 7. PubMed PMID:
25301537.
25: Lerman G, Sharon M, Leibowitz-Amit R, Sidi Y, Avni D. The crosstalk between
IL-22 signaling and miR-197 in human keratinocytes. PLoS One. 2014 Sep
10;9(9):e107467. doi: 10.1371/journal.pone.0107467. eCollection 2014. PubMed
PMID: 25208211; PubMed Central PMCID: PMC4160297.
26: Azad AA, Leibowitz-Amit R*, Eigl BJ, Lester R, Wells JC, Murray RN,
Kollmannsberger C, Heng DY, Joshua AM, Chi KN. A retrospective, Canadian
multi-center study examining the impact of prior response to abiraterone acetate
on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.
PubMed PMID: 25175831. * equal contribution
27: Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah JA, Templeton AJ, Knox
JJ, Tannock IF, Sridhar SS, Joshua AM. Retreatment of men with metastatic
castrate-resistant prostate cancer with abiraterone. Prostate. 2014
Oct;74(14):1462-4. doi: 10.1002/pros.22861. Epub 2014 Aug 11. PubMed PMID:
25111736.
28: Leibowitz-Amit R, Seah JA, Atenafu EG, Templeton AJ, Vera-Badillo FE,
Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Abiraterone acetate in
metastatic castration-resistant prostate cancer: a retrospective review of the
Princess Margaret experience of (I) low dose abiraterone and (II) prior
ketoconazole. Eur J Cancer. 2014 Sep;50(14):2399-407. doi:
10.1016/j.ejca.2014.06.004. Epub 2014 Jul 16. PubMed PMID: 25042152.
29: Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo
FE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score for
metastatic castration-resistant prostate cancer with incorporation of
neutrophil-to-lymphocyte ratio. Cancer. 2014 Nov 1;120(21):3346-52. doi:
10.1002/cncr.28890. Epub 2014 Jul 3. PubMed PMID: 24995769.
30: Leibowitz-Amit R, Mete O, Asa SL, Ezzat S, Joshua AM. Malignant
pheochromocytoma secreting vasoactive intestinal peptide and response to
sunitinib: a case report and literature review. Endocr Pract. 2014
Aug;20(8):e145-50. doi: 10.4158/EP14093.CR. Erratum in: Endocr Pract. 2015
Jan;21(1):94. Lebowitz-Amit, Raya [corrected to Leibowitz-Amit, Raya]. PubMed
PMID: 24936559.
31: Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A,
Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic
role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and
meta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi:
10.1093/jnci/dju124. Print 2014 Jun. Review. PubMed PMID: 24875653.
32: Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N,
Clayton R, Heng DY, Joshua AM, Chi KN. Outcomes with abiraterone acetate in
metastatic castration-resistant prostate cancer patients who have poor
performance status. Eur Urol. 2015 Mar;67(3):441-7. doi:
10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31. PubMed PMID: 24508071.
33: Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D,
Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS,
Joshua AM. Clinical variables associated with PSA response to abiraterone acetate
in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014
Mar;25(3):657-62. doi: 10.1093/annonc/mdt581. Epub 2014 Jan 23. PubMed PMID:
24458472; PubMed Central PMCID: PMC4433513.
34: Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A,
Leibowitz-Amit R, Berger R, Keizman D. Comparison of abiraterone acetate versus
ketoconazole in patients with metastatic castration resistant prostate cancer
refractory to docetaxel. Prostate. 2014 Apr;74(4):433-40. doi:
10.1002/pros.22765. Epub 2013 Dec 11. PubMed PMID: 24338986; PubMed Central
PMCID: PMC4696030.
35: Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P,
Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E,
Tannock IF. Translating clinical trials to clinical practice: outcomes of men
with metastatic castration resistant prostate cancer treated with docetaxel and
prednisone in and out of clinical trials. Ann Oncol. 2013 Dec;24(12):2972-7. doi:
10.1093/annonc/mdt397. Epub 2013 Oct 14. PubMed PMID: 24126362.
36: Leibowitz-Amit R, Joshua AM. The changing landscape in metastatic
castration-resistant prostate cancer. Curr Opin Support Palliat Care. 2013
Sep;7(3):243-8. doi: 10.1097/SPC.0b013e328362ffef. Review. PubMed PMID: 23817317.
37: Leibowitz-Amit R, Joshua AM. Targeting the androgen receptor in the
management of castration-resistant prostate cancer: rationale, progress, and
future directions. Curr Oncol. 2012 Dec;19(Suppl 3):S22-31. doi:
10.3747/co.19.1281. PubMed PMID: 23355790; PubMed Central PMCID: PMC3553559.
38: Leibowitz-Amit R, Sidi Y, Avni D. Aberrations in the micro-RNA biogenesis
machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous
malignant melanoma. Pigment Cell Melanoma Res. 2012 Nov;25(6):740-57. doi:
10.1111/pcmr.12018. Review. PubMed PMID: 22958787.
39: Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, Avni D,
Leibowitz-Amit R. Silencing of a large microRNA cluster on human chromosome 14q32
in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor
1 receptor. Mol Cancer. 2012 Jul 2;11:44. PubMed PMID: 22747855; PubMed Central
PMCID: PMC3444916.
40: Leibowitz-Amit R, Tsarfaty G, Abargil Y, Yerushalmi GM, Horev J, Tsarfaty I.
Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scattering
and tumorigenicity by altering Met-HGF/SF signaling pathways. Cancer Res. 2006
Sep 1;66(17):8687-97. PubMed PMID: 16951184.
41: Yerushalmi GM, Leibowitz-Amit R*, Shaharabany M, Tsarfaty I. Met-HGF/SF signal
transduction induces mimp, a novel mitochondrial carrier homologue, which leads
to mitochondrial depolarization. Neoplasia. 2002 Nov-Dec;4(6):510-22. PubMed
PMID: 12407445; PubMed Central PMCID: PMC1503665.* equal contribution
42: Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, Mor F,
Leibowitz-Amit R, Pevsner E, Akselrod S, Neeman M, Cohen IR, Schwartz M. Passive
or active immunization with myelin basic protein promotes recovery from spinal
cord contusion. J Neurosci. 2000 Sep 1;20(17):6421-30. Erratum in: J Neurosci.
2016 Feb 10;36(6):2075. PubMed PMID: 10964948; PubMed Central PMCID: PMC6772980.
43: Moalem G, Yoles E, Leibowitz-Amit R, Muller-Gilor S, Mor F, Cohen IR,
Schwartz M. Autoimmune T cells retard the loss of function in injured rat optic
nerves. J Neuroimmunol. 2000 Jul 1;106(1-2):189-97. PubMed PMID: 10814797.
44: Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immune
responses can be beneficial for CNS repair. Trends Neurosci. 1999
Jul;22(7):295-9. Review. PubMed PMID: 10370250.
45: Moalem G, Leibowitz-Amit R*, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune
T cells protect neurons from secondary degeneration after central nervous system
axotomy. Nat Med. 1999 Jan;5(1):49-55. PubMed PMID: 9883839. * equal contribution.
Publications פרסומים: Publications
bottom of page